Axillary Metaplastic Breast Carcinoma with Ipsilateral Pectoral Invasive Ductal Carcinoma: An Unusual Presentation

We report a case of axillary metaplastic breast carcinoma (MBC) with triple negative (ER−/PR−/Her2−) phenotype, concurrent with multifocal invasive ductal carcinoma (IDC) of ipsilateral pectoral breast (ER+/PR+/Her2−) in a 60-year-old woman. The two tumors demonstrate different morphology, immunophe...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncological medicine 2014-01, Vol.2014 (2014), p.1-6
Main Authors: Eaves, Jodi M. Matsuura, Carbone, Michele, DeMay, Richard M., Shimizu, David, Comertpay, Sabahattin, Zhang, Lei, Honda, Stacey A.
Format: Article
Language:English
Subjects:
Breast cancer
Case Report
Chemotherapy
Chromosomes
Colleges & universities
Kinases
Medical prognosis
Metastasis
Pathology
Radiation therapy
Smooth muscle
Stem cells
Surgery
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of axillary metaplastic breast carcinoma (MBC) with triple negative (ER−/PR−/Her2−) phenotype, concurrent with multifocal invasive ductal carcinoma (IDC) of ipsilateral pectoral breast (ER+/PR+/Her2−) in a 60-year-old woman. The two tumors demonstrate different morphology, immunophenotype, and opposite response to neoadjuvant chemotherapy of paclitaxol, adriamycin, and cyclophosphamide. Methylation analysis of human androgen receptor (HUMARA) on X-chromosome identified monoclonal pattern of X-chromosome inactivation in MBC and mosaic pattern in the IDC. Stem cell origin of MBC is suggested in this case. Clinicopathological features, imaging findings, biological markers, chemoradiation management, and prognosis of MBC are reviewed in comparison to invasive ductal carcinoma. Our case and literature review suggest that traditional chemotherapy applicable to IDC is less effective towards MBC. However, new chemotherapy protocols targeting stem cell and multimodality management of MBC are promising. Recognition of unusual presentation of MBC will help tailor therapy towards tumor with worse prognosis.
ISSN:2090-6706
2090-6714
DOI:10.1155/2014/938509